Australian researchers found no evidence of reduced allergy development with a Nestlé whey infant formula.
Partially hydrolyzed whey formula is recommended for infants with family history of allergies, but does it really reduce the risk of childhood allergies? According to research published in the Journal of Allergy and Clinical Immunology, it doesn’t.
According to Reuters, which reported on the study, doctors often recommend this type of whey formula because cow’s milk formulas may make allergies more likely and whey’s smaller proteins are believed to be less likely to cause allergies.
Led by Adrian J. Lowe, PhD, of the Royal Children’s Hospital (Melbourne, Australia), researchers recruited 620 infants (before birth) with family history of allergic disease. Infants were randomized to receive one of three formulas: conventional cow’s milk, soy formula, or a partially hydrolyzed whey formula.
Skin prick testing was conducted at 6, 12, and 24 months of age for six common allergens: milk, egg, peanut, dust mite, rye grass, and cat dander. Follow up was performed at 2 and 6 or 7 years.
“Despite current dietary guidelines, we found no evidence to support recommending the use of pHWF at weaning for the prevention o fallergic disease in high-risk infants.”
According to Reuters, the formula was Nestlé’s NAN Hypoallergenic whey product.
Polyphenols: The next generation of prebiotics is ready for liftoff
April 21st 2025Explore the prebiotic health benefits of polyphenols and the positive impact they may have on digestive and immune health. Polyphenols, such as those found in European black elderberry, may be an ideal solution for manufacturers trying to break into the digestive health space.
The Nutritional Outlook Podcast Episode 39: Nutritional Outlook's Ingredients to Watch in 2025
February 25th 2025In this episode, Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2025.